Page last updated: 2024-11-04

pheniramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pheniramine is an antihistamine medication. It is used to treat allergic rhinitis, allergic conjunctivitis, and other allergic reactions. Pheniramine is a histamine H1 receptor antagonist, meaning that it blocks the effects of histamine. Histamine is a chemical that is released by the body in response to allergic reactions. When histamine binds to H1 receptors, it causes symptoms such as sneezing, runny nose, itchy eyes, and hives. By blocking histamine from binding to H1 receptors, pheniramine can relieve these symptoms. Pheniramine is typically taken orally, but it is also available as a nasal spray and eye drops. The effects of pheniramine usually start within 30 minutes of taking the medication. Pheniramine is generally safe for most people, but it can cause side effects such as drowsiness, dry mouth, and dizziness. Pheniramine can also interact with other medications, so it is important to talk to your doctor before taking it.'

Pheniramine: One of the HISTAMINE H1 ANTAGONISTS with little sedative action. It is used in treatment of hay fever, rhinitis, allergic dermatoses, and pruritus. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4761
CHEMBL ID1193
CHEBI ID91591
SCHEMBL ID4796
MeSH IDM0016510

Synonyms (123)

Synonym
LS-14507
BRD-A23072235-050-05-2
3-phenyl-3-(2-pyridyl)-n,n-dimethylpropylamine
p-aminosalicylsaures salz
wln: t6nj byr&2n1&1
nsc-47965
3-phenyl-3-(2-pyridyl)-n,n-dimethylpropylanine
n,n-dimethyl-3-phenyl-3-(2-pyridyl)propylamine
2-[.alpha.-[2-(dimethylamino)ethyl]benzyl]pyridine
86-21-5
nsc47965
2-pyridinepropanamine,n-dimethyl-.gamma.-phenyl-
pheniramine
tripoton
2-[.alpha.-(2-dimethylaminoethyl)benzyl]pyridine
1-phenyl-1-(2-pyridyl)-3-dimethylaminopropane
pyriton
pyridine, 2-[.alpha.-[2-(dimethylamino)ethyl]benzyl]-
feniramine
prophenpyridamine
2-(3-dimethylamino-1-phenylpropyl)pyridine
DIVK1C_000235
KBIO1_000235
n,n-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine
SPECTRUM_001075
BSPBIO_000217
PRESTWICK2_000059
OPREA1_875595
BSPBIO_002380
PRESTWICK3_000059
LOPAC0_000981
SPECTRUM5_001028
AB00053521
nsc 47965
einecs 201-656-2
pheniraminum [inn-latin]
brn 0192445
nci-c60695
2-pyridinepropanamine, n,n-dimethyl-gamma-phenyl-
pyridine, 2-(alpha-(2-(dimethylamino)ethyl)benzyl)-
feniramina [inn-spanish]
pheniramine [inn:ban]
2-(alpha-(2-dimethylaminoethyl)benzyl)pyridine
propheniramine
2-pyridinepropanamine, n,n-dimethyl-.gamma.-phenyl-
n,n-dimethyl-3-phenyl-3-(2-pyridyl)propan-1-amine
dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine
DB01620
IDI1_000235
BPBIO1_000239
KBIO3_001600
KBIO2_001555
KBIOSS_001555
KBIO2_004123
KBIO2_006691
KBIOGR_001311
SPBIO_001274
PRESTWICK0_000059
SPECTRUM2_001277
SPBIO_002138
NINDS_000235
SPECTRUM3_000760
SPECTRUM4_000966
PRESTWICK1_000059
NCGC00162306-01
NCGC00015831-03
CHEMBL1193 ,
pheniramine (inn)
D08355
dimethyl-(3-phenyl-3-pyridin-2-yl-propyl)-amine
bdbm50017656
n,n-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine
CCG-205061
NCGC00015831-02
feniramina
5-22-10-00487 (beilstein handbook reference)
unii-134fm9zz6m
pheniraminum
134fm9zz6m ,
FT-0603298
gtpl7267
dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine
AKOS022110089
n,n-dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine
STL329242
1-phenyl-1-(2-pyridyl)-3-di-methylaminopropane
pheniramine [who-dd]
pheniramine [mart.]
2-(.alpha.-(2-dimethylaminoethyl)benzyl)pyridine
pheniramine [mi]
155683-10-6
n,n-dimethyl-.gamma.-phenyl-2-pyridinepropanamine
(+/-)-pheniramine
pyridine, 2-(.alpha.-(2-(dimethylamino)ethyl)benzyl)-
pheniramine [vandf]
pheniramine [inn]
SCHEMBL4796
dexchlorpheniramine maleate ep impurity a
n,n-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine #
metron (salt/mix)
inhiston (salt/mix)
pm 241 (salt/mix)
pyridine, 2[alpha-(2-dimethylaminoethyl)benzyl]
IJHNSHDBIRRJRN-UHFFFAOYSA-N
AB00053521_18
AB00053521_19
DTXSID0023454
CHEBI:91591
brompheniramine maleate imp. c (ep); brompheniramine imp. c (ep); (3rs)-n,n-dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine; pheniramine; brompheniramine maleate impurity c; brompheniramine impurity c
pheniramine 1.0 mg/ml in methanol
SBI-0050954.P004
NCGC00015831-07
A900022
mfcd31699964
3-(phenyl-4-d)-n,n-dimethyl-3-(2-pyridyl)-1-propanamine
SY246337
2122800-15-9
Q656259
prophenpyridamine; pyriton
BRD-A23072235-050-09-4
SDCCGSBI-0050954.P005
NCGC00015831-12
EN300-18563895

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with pheniramine maleate (H₁ antagonist, 3 mg/kg) blocked both venom-induced augmentation of PBG response and pulmonary edema."( Indian red scorpion venom-induced augmentation of cardio-respiratory reflexes and pulmonary edema involve the release of histamine.
Deshpande, SB; Dutta, A, 2011
)
0.69

Toxicity

ExcerptReferenceRelevance
" It is also safe and effective at the dosage studied in children undergoing MRI."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.31
" Histamine was applied at 10(-9),10(-8), 10(-7),10(-6), and 10(-5) M for 16 h into the cultures and the highest dose was found to be the most toxic one."( Contribution of the histaminergic receptor subtypes to histamine-induced cerebellar granular neurotoxicity.
Buyukokuroglu, ME; Gepdiremen, A; Hacimuftuoglu, A; Suleyman, H,
)
0.13
" Although H1-antihistamines rarely elicit cutaneous adverse effects, there have been a few reports in the literature implicating them in causing fixed drug eruption, particularly the piperazine derivatives (hydroxyzine, cetirizine, levocetirizine), and loratadine."( Pheniramine maleate: an apparently safe drug causing bullous fixed drug eruption.
Arora, P; Gupta, A; Malhotra, P; Sardana, K, 2018
)
1.92

Pharmacokinetics

ExcerptReferenceRelevance
"5 × 10(-7)g/L based on a signal-to-noise of 3 (S/N=3) with 751- to 1372-fold increases in detection sensitivity for analytes, and it was successfully applied to the pharmacokinetic study of three antihistamines in human urine after an oral administration."( Trace analysis of three antihistamines in human urine by on-line single drop liquid-liquid-liquid microextraction coupled to sweeping micellar electrokinetic chromatography and its application to pharmacokinetic study.
Chen, G; Chen, Y; Gao, W; Xi, J; Xu, N; Yang, J, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The quantitative determinations of codeine phosphate, guaifenesin, pheniramine maleate, phenylpropanolamine hydrochloride, and pyrilaminemaleate in a liquid dosage form are described. After rats were injected intrathecally with diphenhydramine and Pheniramine, the dose-response curves were obtained.

ExcerptRelevanceReference
"The quantitative determinations of codeine phosphate, guaifenesin, pheniramine maleate, phenylpropanolamine hydrochloride, and pyrilamine maleate in a liquid dosage form are described."( Quantitative determinations of codeine phosphate, guaifenesin, pheniramine maleate, phenylpropanolamine hydrochloride, and pyrilamine maleate in an expectorant by high-pressure liquid chromatography.
Ghanekar, AG; Gupta, VD, 1977
)
0.73
" The three preparations were found to vary greatly in patient comfort and acceptability but were not different in their ability to ameliorate the itching, tearing, redness, edema and discomfort when dosed topically for the relief of allergic conjunctivitis."( A double-masked comparison of ocular decongestants as therapy for allergic conjunctivitis.
deFaller, JM; Lanier, BQ; Smith, JP; Tremblay, N, 1983
)
0.27
"The dosage of thiopental was 50 mg per kg for infants under 6 months of age, 35 mg per kg between six and 12 months, and 25 mg per kg for older children."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.31
" It is also safe and effective at the dosage studied in children undergoing MRI."( Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
Alp, H; Altinkaynak, S; Güler, I; Orbak, Z, 2002
)
0.31
" After rats were injected intrathecally with diphenhydramine and pheniramine, the dose-response curves were obtained."( Spinal anesthesia with diphenhydramine and pheniramine in rats.
Chen, YC; Chen, YW; Chu, CC; Hung, CH; Li, ZY; Wang, JJ, 2011
)
0.87
" Drug dosage was determined by initial VAS (visual analog scale) scores."( A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus.
Ahuja, RB; Gupta, GK, 2013
)
0.39
" The dose-response curve for ACh (0."( In vitro study of acetylcholine and histamine induced contractions in colon and rectum of adult and neonate rats.
Mandal, MB; Singh, S,
)
0.13
" An optimized dose-response curve is then presented, introducing (±) amphetamine hydrochloride (0."( A Molecularly Imprinted Polymer-based Dye Displacement Assay for the Rapid Visual Detection of Amphetamine in Urine.
Arreguin-Campos, R; Caldara, M; Cleij, TJ; Diliën, H; Eersels, K; Heidt, B; Jimenez-Monroy, KL; Lowdon, JW; Rogosic, R; van Grinsven, B, 2020
)
0.56
"Strict adherence to pharmacological dosage regimens is a prerequisite to the success of most treatments, particularly for patients in drug abuse programs."( Urinalysis based assessment of compliance and drug use patterns in patients prescribed tramadol: A cross-sectional study from a tertiary care centre.
Ghosh, S; Jain, R; Saifi, N; Sarkar, S, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Pheniramine H1-Antihistamine Action87

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94660.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1061889Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (246)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990129 (52.44)18.7374
1990's28 (11.38)18.2507
2000's29 (11.79)29.6817
2010's43 (17.48)24.3611
2020's17 (6.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.93 (24.57)
Research Supply Index5.71 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index147.47 (26.88)
Search Engine Supply Index2.10 (0.95)

This Compound (79.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (9.89%)5.53%
Reviews4 (1.47%)6.00%
Case Studies30 (10.99%)4.05%
Observational1 (0.37%)0.25%
Other211 (77.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Pheniramine Maleate 20 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With [NCT02730364]Phase 30 participants (Actual)Interventional2017-02-01Withdrawn(stopped due to The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.)
Comparison of Tolerability Between Two Allergy Drops [NCT01390961]Phase 448 participants (Anticipated)Interventional2011-08-31Enrolling by invitation
A Randomized, Double-blind, Prospective, Multicentric, Superior Efficacy and Safety of Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal Due [NCT01533220]Phase 3132 participants (Actual)Interventional2013-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]